
1. cell chem biol. 2020 jul 16;27(7):806-816.e8. doi:
10.1016/j.chembiol.2020.04.001. epub 2020 apr 30.

inhibition resistance-refractory p. falciparum kinase pkg delivers
prophylactic, blood stage, transmission-blocking antiplasmodial activity.

vanaerschot m(1), murithi jm(1), pasaje cfa(2), ghidelli-disse s(3), dwomoh l(4),
bird m(5), spottiswoode n(1), mittal n(6), arendse lb(7), owen es(8), wicht
kj(1), siciliano g(9), bösche m(3), yeo t(1), kumar trs(1), mok s(1), carpenter
ef(10), giddins mj(11), sanz o(12), ottilie s(6), alano p(9), chibale k(7),
llinás m(13), uhlemann ac(11), delves m(14), tobin ab(4), doerig c(15), winzeler 
ea(6), lee mcs(10), niles jc(2), fidock da(16).

author information: 
(1)department microbiology immunology, columbia university irving medical 
center, new york, ny 10032, usa.
(2)department biological engineering, massachusetts institute technology,
cambridge, 02139, usa.
(3)cellzome gmbh, glaxosmithkline, 69117 heidelberg, germany.
(4)centre translational pharmacology, institute molecular cell systems
biology, university glasgow, glasgow g12 8qq, uk, scotland.
(5)department microbiology, monash university, melbourne, vic 3800, australia.
(6)school medicine, university california san diego, la jolla, ca 92093,
usa.
(7)drug discovery development centre (h3d), south african medical research
council drug discovery development research unit, department chemistry &
institute infectious disease molecular medicine, university cape town, 
rondebosch 7701, south africa.
(8)department biochemistry molecular biology, pennsylvania state
university, university park, pa 16801, usa; huck center malaria research,
pennsylvania state university, university park, pa 16802, usa.
(9)dipartimento di malattie infettive, istituto superiore di sanità, rome, italy.
(10)wellcome sanger institute, wellcome genome campus, hinxton, cambridgeshire,
uk.
(11)division infectious diseases, columbia university irving medical center,
new york, ny 10032, usa.
(12)diseases developing world global health pharma unit, glaxosmithkline, 
28760 tres cantos, spain.
(13)department biochemistry molecular biology, pennsylvania state
university, university park, pa 16801, usa; huck center malaria research,
pennsylvania state university, university park, pa 16802, usa; department of
chemistry, pennsylvania state university, university park, pa 16802, usa.
(14)department infection biology, london school hygiene tropical
medicine, london wc1e 7ht, uk.
(15)department microbiology, monash university, melbourne, vic 3800,
australia; school health biomedical sciences, rmit university, bundoora
vic 3083, australia.
(16)department microbiology immunology, columbia university irving medical
center, new york, ny 10032, usa; division infectious diseases, columbia
university irving medical center, new york, ny 10032, usa. electronic address:
df2260@cumc.columbia.edu.

the search antimalarial chemotypes modes action unrelated existing
drugs intensified recent failure first-line therapies across
southeast asia. here, show trisubstituted imidazole mmv030084
potently inhibits hepatocyte invasion plasmodium sporozoites, merozoite egress
from asexual blood stage schizonts, male gamete exflagellation. metabolomic, 
phosphoproteomic, chemoproteomic studies, validated conditional
knockdown parasites, molecular docking, recombinant kinase assays, identified
cgmp-dependent protein kinase (pkg) primary target mmv030084. pkg is
known play essential roles plasmodium invasion egress host
cells, matching mmv030084's activity profile. resistance selections gene
editing identified tyrosine kinase-like protein 3 low-level resistance
mediator pkg inhibitors, pkg never mutated pressure. these
studies highlight pkg resistance-refractory antimalarial target throughout
the plasmodium life cycle promote mmv030084 promising plasmodium
pkg-targeting chemotype.

copyright © 2020 authors. published elsevier ltd.. rights reserved.

doi: 10.1016/j.chembiol.2020.04.001 
pmcid: pmc7369637
pmid: 32359426 

conflict interest statement: declaration interests authors declare no
competing interests.

